- Home
- SE vs SNY Comparison
SE vs SNY Comparison
Compare SE & SNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SE | SNY |
|---|---|---|
| Founded | 2009 | 1994 |
| Country | Singapore | France |
| Employees | N/A | 74846 |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 77.8B | 116.8B |
| IPO Year | 2017 | N/A |
Fundamental Metrics
Financial Performance| Metric | SE | SNY |
|---|---|---|
| Price | $86.71 | $43.94 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 11 | 6 |
| Target Price | ★ $179.54 | $61.50 |
| AVG Volume (30 Days) | ★ 6.4M | 3.7M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | ★ 3.67% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $25.20 | $3.01 |
| Revenue Next Year | $17.80 | $5.80 |
| P/E Ratio | $49.15 | ★ $6.14 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $77.05 | $43.49 |
| 52 Week High | $199.30 | $59.17 |
Technical Indicators
Market Signals| Indicator | SE | SNY |
|---|---|---|
| Relative Strength Index (RSI) | 32.72 | 34.63 |
| Support Level | $77.05 | N/A |
| Resistance Level | $161.37 | $48.97 |
| Average True Range (ATR) | 4.47 | 0.68 |
| MACD | -0.80 | -0.29 |
| Stochastic Oscillator | 28.84 | 8.84 |
Price Performance
Historical ComparisonAbout SE Sea Limited each representing one
Sea started as a gaming business, Garena, but in 2015 expanded into e-commerce. Sea operates Southeast Asia's largest e-commerce company, Shopee, in terms of gross merchandise value. Shopee is a hybrid C2C and B2C marketplace platform operating in Indonesia, Taiwan, Vietnam, Thailand, Malaysia, the Philippines, and Brazil. For Garena, Free Fire is the key revenue generating game. Sea's third business, SeaMoney, provides lending, payment, digital banking, and insurance services.As of March 31, 2025, Forrest Xiaodong Li, the founder, chairman and CEO, owned 59.1% of voting power. Tencent owned 18.5% of issued shares with no voting power.
About SNY Sanofi ADS
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for approximately 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.